74 related articles for article (PubMed ID: 26706657)
1. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
[TBL] [Abstract][Full Text] [Related]
2. Sirtuins and Metabolism Biomarkers in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: a Correlation Study with Clinical Outcomes and Cognitive Impairments.
Foolad F; Samadi-Bahrami Z; Khodagholi F; Nabavi SM; Moore GRW; Javan M
Mol Neurobiol; 2024 Jun; 61(6):3442-3460. PubMed ID: 37995076
[TBL] [Abstract][Full Text] [Related]
3. Assessment of serum inflammatory parameters in RRMS and SPMS patients.
Nowak-Kiczmer M; Niedziela N; Czuba ZP; Sowa P; Wierzbicki K; Lubczyński M; Adamczyk-Sowa M
Neurol Res; 2024 Jun; 46(6):495-504. PubMed ID: 38697017
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers of disability worsening in inactive primary progressive multiple sclerosis.
Baeva ME; Tottenham I; Koch M; Camara-Lemarroy C
J Neuroimmunol; 2024 Feb; 387():578268. PubMed ID: 38157653
[TBL] [Abstract][Full Text] [Related]
5. Folate receptor alpha autoantibodies in the serum of patients with relapsing-remitting multiple sclerosis (RRMS).
Mashayekhi F; Hadipour E; Shabani S; Salehi Z
Clin Neurol Neurosurg; 2024 Feb; 237():108161. PubMed ID: 38325038
[TBL] [Abstract][Full Text] [Related]
6. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Lunemann JD; Hegen H; Villar LM; Rejdak K; Sao-Aviles A; Carbonell-Mirabent P; Sastre-Garriga J; Mongay-Ochoa N; Berek K; Martínez-Yélamos S; Pérez-Miralles F; Abdelhak A; Bachhuber F; Tumani H; Lycke JN; Rosenstein I; Alvarez-Lafuente R; Castillo-Trivino T; Otaegui D; Llufriu S; Blanco Y; Sánchez López AJ; Garcia Merino JA; Fissolo N; Gutierrez L; Villacieros-Álvarez J; Monreal E; Valls-Carbó A; Wiendl H; Montalban X; Comabella M
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200270. PubMed ID: 38912898
[TBL] [Abstract][Full Text] [Related]
7. Alpha Calcitonin Gene-related Peptide, Neuropeptide Y, and Substance P as Biomarkers for Diagnosis and Disease Activity and Severity in Multiple Sclerosis.
Al-Keilani MS; Almomani BA; Jaradat SA; Al-Sawalha NA; Qawasmeh MA
CNS Neurol Disord Drug Targets; 2024; 23(4):512-524. PubMed ID: 37013432
[TBL] [Abstract][Full Text] [Related]
8. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.
Hohlfeld R; Dornmair K; Meinl E; Wekerle H
Lancet Neurol; 2016 Feb; 15(2):198-209. PubMed ID: 26724103
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.
Shirani A; Okuda DT; Stüve O
Neurotherapeutics; 2016 Jan; 13(1):58-69. PubMed ID: 26729332
[TBL] [Abstract][Full Text] [Related]
10. B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.
Claes N; Fraussen J; Stinissen P; Hupperts R; Somers V
Front Immunol; 2015; 6():642. PubMed ID: 26734009
[TBL] [Abstract][Full Text] [Related]
11. Quantified CSF antibody reactivity against myelin in multiple sclerosis.
Sun X; Bakhti M; Fitzner D; Schnaars M; Kruse N; Coskun Ü; Kremser C; Willecke K; Kappos L; Kuhle J; Simons M
Ann Clin Transl Neurol; 2015 Dec; 2(12):1116-23. PubMed ID: 26734662
[TBL] [Abstract][Full Text] [Related]
12. B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation.
Michel L; Touil H; Pikor NB; Gommerman JL; Prat A; Bar-Or A
Front Immunol; 2015; 6():636. PubMed ID: 26732544
[TBL] [Abstract][Full Text] [Related]
13. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.
Hohlfeld R; Dornmair K; Meinl E; Wekerle H
Lancet Neurol; 2016 Mar; 15(3):317-31. PubMed ID: 26724102
[TBL] [Abstract][Full Text] [Related]
14. Illuminating vitamin D effects on B cells--the multiple sclerosis perspective.
Rolf L; Muris AH; Hupperts R; Damoiseaux J
Immunology; 2016 Mar; 147(3):275-84. PubMed ID: 26714674
[TBL] [Abstract][Full Text] [Related]
15. PAMP-DAMPs interactions mediates development and progression of multiple sclerosis.
Hernández-Pedro N; Magana-Maldonado R; Ramiro AS; Pérez-De la Cruz V; Rangel-López E; Sotelo J; Pineda B
Front Biosci (Schol Ed); 2016 Jan; 8(1):13-28. PubMed ID: 26709893
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study.
Shinto L; Marracci G; Mohr DC; Bumgarner L; Murchison C; Senders A; Bourdette D
PLoS One; 2016; 11(1):e0147195. PubMed ID: 26799942
[TBL] [Abstract][Full Text] [Related]
18. Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.
Michell-Robinson MA; Moore CS; Healy LM; Osso LA; Zorko N; Grouza V; Touil H; Poliquin-Lasnier L; Trudelle AM; Giacomini PS; Bar-Or A; Antel JP
Ann Clin Transl Neurol; 2016 Jan; 3(1):27-41. PubMed ID: 26783548
[TBL] [Abstract][Full Text] [Related]
19. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Spelman T; Mekhael L; Burke T; Butzkueven H; Hodgkinson S; Havrdova E; Horakova D; Duquette P; Izquierdo G; Grand'Maison F; Grammond P; Barnett M; Lechner-Scott J; Alroughani R; Trojano M; Lugaresi A; Granella F; Pucci E; Vucic S;
Eur J Neurol; 2016 Apr; 23(4):729-36. PubMed ID: 26782663
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
